-
MDA 2026: Duvyzat shows DMD benefits even at lower dose levels
Treatment with Duvyzat (givinostat) was associated with functional gains in boys with Duchenne muscular dystrophy (DMD)
-
Sarepta trial enrolling for ELEVIDYS treatment with enhanced immunosuppression in non-ambulant individuals
Sarepta therapeutics is seeking to enroll 25 non-ambulant individuals with Duchenne in a clinical trial








